Aldesleukin Terminated Phase 2 Trials for Metastatic Melanoma / Skin Cancers Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01369875Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
NCT00610311Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
NCT00612222Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
NCT01495572Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells